Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations for 2003: Agricultural programsU.S. Government Printing Office, 2002 - United States |
From inside the book
Results 1-5 of 100
Page 7
... patients ; and bioengineered plants and animals . These achievements represent an enormous potential for saving lives , improving the quality of life and stimulating economic growth . I caution that along with the potential benefits ...
... patients ; and bioengineered plants and animals . These achievements represent an enormous potential for saving lives , improving the quality of life and stimulating economic growth . I caution that along with the potential benefits ...
Page 19
... patients versus control samples . Also , we are actively engaged in exploring the use of the new technologies of ... patient's blood along 15 19.
... patients versus control samples . Also , we are actively engaged in exploring the use of the new technologies of ... patient's blood along 15 19.
Page 20
... patient's blood along with enzymes to produce the information needed for a reliable laboratory diagnosis . Generic ... patients . The Congressional Budget Office reported in a study completed in 1998 that the purchase of generic drugs ...
... patient's blood along with enzymes to produce the information needed for a reliable laboratory diagnosis . Generic ... patients . The Congressional Budget Office reported in a study completed in 1998 that the purchase of generic drugs ...
Page 21
... Patient Safety / Medical Errors This past year the media paid a great deal of attention to human clinical trials ... patients involved in clinical trials . We must ensure the accuracy , safety and effectiveness of the data gathered ...
... Patient Safety / Medical Errors This past year the media paid a great deal of attention to human clinical trials ... patients involved in clinical trials . We must ensure the accuracy , safety and effectiveness of the data gathered ...
Page 22
... patients has been improved by two new measures . One of them is FDA's requirement of evidence that all but the lowest - risk reprocessed single - use medical devices - such instruments as laparoscopy scissors and balloon angioplasty ...
... patients has been improved by two new measures . One of them is FDA's requirement of evidence that all but the lowest - risk reprocessed single - use medical devices - such instruments as laparoscopy scissors and balloon angioplasty ...
Other editions - View all
Common terms and phrases
90 percent act on 90 activities additional adverse events Agency Agency's Animal Drugs antimicrobial appropriate approved assessment associated bioterrorism blood Bonilla Bovine Spongiform Encephalopathy breast implant budget CFSAN clinical Committee compliance conduct consumers contamination costs Counter Terrorism CRAWFORD database dietary supplements disease domestic drug applications Drugs and Feeds electronic ensure establishments Estimate evaluate facilities Farm Credit Farm Credit System FDA's Federal fiscal Food and Drug food safety foodborne illness funding guidance HACCP Human Drugs implementation import increase industry inspections issues KAPTUR labeling laboratory Listeria monocytogenes loans mammography manufacturing medical devices medical products million monitoring MQSA Office pathogens patients PDUFA pediatric percent FY Performance Goals premarket proposed protect public health regulations regulatory request requirements Response Review and act risk Salmonella standards submissions surveillance System terrorist Undeclared color User Fees vaccines
Popular passages
Page 620 - October 31, 1977) provides that none of the funds appropriated or otherwise made available by this Act to the...
Page 438 - ... payment for publication of technical and Informational materials in professional and trade Journals...
Page 1193 - The four regulatory agencies that issued today's stateaents are the Office of the Comptroller of the Currency (OCC) , the Federal Deposit Insurance Corporation (FDIC), the Federal Reserve Board (FRB...
Page 1188 - Act of 1993 (GPRA) seeks to improve the effectiveness, efficiency, and accountability of federal programs by requiring federal agencies to set goals for program performance and to report on annual performance compared with the goals.
Page 21 - A standard for the design, conduct, performance, monitoring, auditing, recording, analyses, and reporting of clinical trials that provides assurance that the data and reported results are credible and accurate, and that the rights, integrity, and confidentiality of trial subjects are protected.
Page 388 - II is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.
Page 326 - Available from National Technical Information Service, Springfield, VA 22151. ious requirements of the Environmental Protection Agency (EPA), the Nuclear Regulatory Commission (NRC), and other Federal and State agencies. The ultimate objective of these models is general prediction of the chemical concentrations to which organisms, including man, may be exposed following short or long-term releases of the chemical to the environment. Due to differences in intended uses, the models range in...
Page 306 - ... (A) officers and employees of the Food and Drug Administration, employees under contract with the Food and Drug Administration who work in facilities owned or leased for the Food and Drug Administration, advisory committees, and costs related to such officers, employees, and committees, (B) management of information, and the acquisition, maintenance, and repair of computer resources, (C) leasing, maintenance, renovation, and repair of facilities and acquisition, maintenance, and repair of fixtures,...
Page 260 - I would be happy to provide that information for the record. (The information follows...
Page 301 - Section 736 (g) (2) (B), states that fees: shall only be collected and available to defray increases in the costs of the resources allocated for the process for the review of human drug applications (including increases in such costs for an additional number of fulltime equivalent positions...